New blood thinner tested for rare clotting disorder
NCT ID NCT00861692
First seen Jan 11, 2026 · Last updated Jun 17, 2026 · Updated 23 times
Summary
This study looked at how well the drug argatroban works in 20 adults with a condition called heparin-induced thrombocytopenia Type II, where the blood thinner heparin causes low platelets and raises clot risk. Participants received argatroban to prevent new or worsening blood clots. Researchers tracked deaths, new clots, amputations, and bleeding to understand the drug's safety and effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPARIN-INDUCED THROMBOCYTOPENIA TYPE II are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Study site
Saint-Etienne, France
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.